Tom Plitz, PhD, CEO

Tom Plitz combines a strong R&D background with entrepreneurial experience and strong leadership skills. Prior to joining Precirix, he was the CEO of Chord Therapeutics, a clinical stage biotech company active in neurology which was sold to Merck. Before that he served as CSO of Wilson Therapeutics acquired by Alexion. Earlier in his career he worked in several pharma companies in R&D roles with increasing responsibilities. He obtained a Master and PhD degree from the Technical University of Munich, focusing on Immunology and Cell Biology.